Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
SABS 
SAB Biotherapeutics Inc (SABS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/11/2025: SABS (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
5 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $9.2
1 Year Target Price $9.2
| 4 | Strong Buy |
| 1 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -19% | Avg. Invested days 35 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/11/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 22.07M USD | Price to earnings Ratio - | 1Y Target Price 9.2 |
Price to earnings Ratio - | 1Y Target Price 9.2 | ||
Volume (30-day avg) 5 | Beta 0.55 | 52 Weeks Range 1.00 - 5.01 | Updated Date 09/12/2025 |
52 Weeks Range 1.00 - 5.01 | Updated Date 09/12/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.99 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -36463.03% |
Management Effectiveness
Return on Assets (TTM) -56.81% | Return on Equity (TTM) -127.48% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22932712 | Price to Sales(TTM) 192.43 |
Enterprise Value 22932712 | Price to Sales(TTM) 192.43 | ||
Enterprise Value to Revenue 1.21 | Enterprise Value to EBITDA -1.49 | Shares Outstanding 10411100 | Shares Floating 7555411 |
Shares Outstanding 10411100 | Shares Floating 7555411 | ||
Percent Insiders 14.29 | Percent Institutions 18.66 |
Upturn AI SWOT
SAB Biotherapeutics Inc
Company Overview
History and Background
SAB Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2014. They are focused on developing and manufacturing novel polyclonal antibody therapeutics to treat and prevent infectious diseases, immune system disorders, and cancer using their DiversitAbu2122 platform. SAB initially focused on infectious diseases before expanding its pipeline.
Core Business Areas
- DiversitAbu2122 Platform: SAB's core technology platform that produces human polyclonal antibodies using genetically engineered cattle.
- Therapeutic Development: The development of polyclonal antibody therapeutics for infectious diseases, immune system disorders and oncology.
- Manufacturing: In-house manufacturing capabilities for their antibody products.
Leadership and Structure
Eddie J. Sullivan, PhD is the Co-Founder, President & CEO. The organizational structure involves research and development, clinical operations, manufacturing, and commercialization divisions.
Top Products and Market Share
Key Offerings
- SAB-185 (COVID-19 Therapeutic): SAB-185 was a polyclonal antibody therapy developed for COVID-19. Clinical trials were conducted, however, Emergency Use Authorization was not obtained. Competitors included Regeneron (REGN) with REGEN-COV (now withdrawn) and Eli Lilly (LLY) with bamlanivimab (also withdrawn).
- SAB-142 (Influenza Therapeutic): A polyclonal antibody therapeutic targeting influenza. Currently in preclinical/early clinical development. Competitors include Roche (ROG) with Tamiflu and other influenza vaccines and therapeutics from various pharmaceutical companies.
Market Dynamics
Industry Overview
The biopharmaceutical industry is highly competitive and constantly evolving, with a focus on developing innovative therapies for unmet medical needs. Polyclonal antibody therapeutics represent a growing area within this industry.
Positioning
SAB Biotherapeutics is positioned as an innovator in the polyclonal antibody therapeutics space, leveraging a unique platform to produce fully human antibodies. Their competitive advantage lies in their DiversitAbu2122 platform, which allows them to rapidly generate and scale up antibody production.
Total Addressable Market (TAM)
The total addressable market for infectious disease therapeutics is substantial, estimated to be in the billions of dollars annually. SAB's positioning within this TAM depends on the success of its pipeline and ability to secure regulatory approvals and market access.
Upturn SWOT Analysis
Strengths
- Innovative DiversitAbu2122 platform
- Potential for rapid antibody generation and scaling
- Experienced leadership team
- In-house manufacturing capabilities
Weaknesses
- Limited number of products currently in advanced clinical stages
- Reliance on a single technology platform
- Significant capital requirements for drug development
- Past acquisition offer withdrawn
Opportunities
- Expanding pipeline to address multiple therapeutic areas
- Partnerships and collaborations with larger pharmaceutical companies
- Government funding and support for pandemic preparedness
- Potential for breakthrough therapies for unmet medical needs
Threats
- Clinical trial failures
- Regulatory hurdles and delays
- Competition from established pharmaceutical companies
- Intellectual property disputes
- Fluctuations in market capitalization
Competitors and Market Share
Key Competitors
- REGN
- LLY
- GSK
- SNY
Competitive Landscape
SAB Biotherapeutics competes with established pharmaceutical companies in the infectious disease and immunology space. Their DiversitAb platform offers a unique approach, but they face challenges in scaling production and securing regulatory approvals.
Growth Trajectory and Initiatives
Historical Growth: Historical growth data is limited due to the company's relatively short operating history and transition to a private company.
Future Projections: Future projections are unavailable as SAB Biotherapeutics became a private company in December 2023.
Recent Initiatives: Recent initiatives focused on advancing their clinical pipeline, securing partnerships, and strengthening their manufacturing capabilities.
Summary
SAB Biotherapeutics is an innovative company with a novel antibody platform. While they possess a unique technology and experienced leadership, the company is early stage and faces regulatory and competitive challenges. The success hinges on its pipeline advancing through clinical trials and achieving regulatory approval. The going private transaction is allowing them to restructure. It needs to overcome past set backs.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SAB Biotherapeutics Website
- Company Press Releases
- SEC Filings (historical)
- Third-Party Market Research Reports
Disclaimers:
This analysis is based on publicly available information and represents a snapshot in time. Market conditions and company performance are subject to change. This is not financial advice. The AI rating is an estimate.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About SAB Biotherapeutics Inc
Exchange NASDAQ | Headquaters Miami Beach, FL, United States | ||
IPO Launch date 2021-02-09 | CEO & Executive Chairman Mr. Samuel J. Reich | ||
Sector Healthcare | Industry Biotechnology | Full time employees 63 | |
Full time employees 63 | |||
SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of human polyclonal immunotherapeutic antibodies to address immune system disorders. It has applied advanced genetic engineering to develop transchromosomic for hyperimmunization and plasma collection, as well as develops product to treat diseases, including type 1 diabetes (T1D) and other autoimmune disorders. In addition, its lead product candidate SAB-142, a human, multi-target anti-thymocyte globulin treatment, currently under Phase 2b clinical trials in delaying the onset or progression of type 1. SAB Biotherapeutics, Inc. was founded in 2014 and is headquartered in Miami Beach, Florida.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.